Editorial
Nephrogenic Fibrosing Dermopathy/Nephrogenic Systemic Fibrosis—Setting the Record Straight

https://doi.org/10.1016/j.semarthrit.2005.09.005Get rights and content

References (19)

There are more references available in the full text version of this article.

Cited by (80)

  • Gadolinium Retention and Toxicity—An Update

    2017, Advances in Chronic Kidney Disease
  • Gadolinium deposition disease: Initial description of a disease that has been around for a while

    2016, Magnetic Resonance Imaging
    Citation Excerpt :

    Based on these results, we propose a name for this presumed disease process in subjects with normal renal function and gadolinium toxicity, Gadolinium Deposition Disease (GDD). At least 60% of our subjects showed a glove-and-sock distribution of disease associated with intense sharp “pins and needles” or burning pain, and skin changes, resembling NSF [11–13]. Other examples of similar but less severe changes compared to NSF include: tissue in NSF is often described as woody and joint contractions severe, whereas subjects in our survey have reported as spongy or rubbery, and joint flexures minimal.

  • The kidney and rheumatic disease

    2015, Rheumatology: Sixth Edition
  • Adverse events caused by MRI contrast agents: Implications for radiographers who inject

    2012, Radiography
    Citation Excerpt :

    In addition the RCR26 states that the appropriate use of questionnaire screening including history of renal disease, prior kidney surgery, hypertension, gout, diabetes mellitus may be adequate and if there are any positive responses then serum creatinine levels should be obtained. With extended roles for MRI radiographers, practice is rapidly expanding especially in the areas of prescribing and administration of contrast agents whilst there are now several MRI radiographers undertaking image interpretation.20 Radiographers are well placed in contributing to the establishment of departmental policies for the safe use and administration of contrast agents as per the Patient Group Directives.38

  • Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents

    2011, Advances in Chronic Kidney Disease
    Citation Excerpt :

    The association of NSF with one particular factor remained elusive. Information from the NSF registry before 2006 led to the suspicion that a contrast agent was an important common factor among affected patients, although confirmation of this suspicion was complicated by incomplete and unavailable medical records.23 It was the report by Grobner from Austria that ignited the field on making the remarkable association of NSF with an antecedent exposure to a GBCA formulation containing gadodiamide (Omniscan, GE Healthcare Inc., Princeton, NJ) in 5 of 9 patients with ESRD who received triple doses for magnetic resonance (MR) angiograms.24

  • The use of gadolinium for arterial interventions

    2011, Annals of Vascular Surgery
    Citation Excerpt :

    Other clinical manifestations include pain, swelling, hyperpigmentation, erythema, pruritis, and muscle weakness. The fibrotic process is not limited to the skin and multiple studies have proven that systemic involvement is common with progression of the disease.42,43 Treatment for the disease is limited and complete resolution is very rare.

View all citing articles on Scopus
View full text